A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Clinical trial NCT04001777 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04001777
Sponsor: Ascentage Pharma Group Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

EGFR Positive Non-small Cell Lung Cancer

Start date: 2019-07-04
Primary completion: 2025-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.